Background-Recent genome-wide association studies have demonstrated an association between MYH6, the gene encoding α-myosin heavy chain (α-MHC), and sinus node function in the general population. Moreover, a rare MYH6 variant, R721W, predisposing susceptibility to sick sinus syndrome has been identified. However, the existence of disease-causing MYH6 mutations for familial sick sinus syndrome and their underlying mechanisms remain unknown. Methods and Results-We screened 9 genotype-negative probands with sick sinus syndrome families for mutations in MYH6
S ick sinus syndrome (SSS) is a common arrhythmia often associated with aging, structural heart diseases, or surgical injury, but can also occur in a familial form. 1 Several studies have demonstrated genetic mutations in both sporadic and familial cases of SSS. [2] [3] [4] Affected ion channel or ion channelassociated genes identified to date include sodium channel, Nav1.5 (SCN5A), 2 ankyrin-B (ANK2), 3 and hyperpolarizationactivated channel (HCN4). 4 Mutations in HCN4 result in sinus node dysfunction caused by a reduction of the pacemaker current, whereas SCN5A mutations lead to conduction delay within the sinus node or exit block. 5 MYH6 and MYH7 encode the homologous myosin heavy chain (MHC) isoforms α-MHC and β-MHC, respectively, in cardiomyocytes, which play pivotal roles in the organization of sarcomeric structures and muscle contraction. [6] [7] [8] MYH7 is predominantly expressed in the adult ventricle, whereas MYH6 is mainly expressed in the fetal heart and adult atrium. 9 MYH7 is a well-established causative gene with over 300 mutations responsible for hypertrophic cardiomyopathy and dilated cardiomyopathy, 10, 11 whereas more limited MYH6 mutations have been reported in cardiomyopathy 12, 13 and congenital heart disease, such as atrial septal defect. 7, [14] [15] [16] [17] On the contrary, recent genome-wide association studies demonstrated that a common nonsynonymous variant A1101V in MYH6 was associated with an increased resting heart rate, [17] [18] [19] whereas another rare nonsynonymous variant (resulting in R721W) was associated with a high risk of SSS. 20 Moreover, heterozygous zebrafish carrying the MYH6 mutation N695K (MYH6 hu/423/+ ) displayed partial atrial contractile defects. 21 Based on these observations, it is conceivable that some MYH6 variations impair the sarcomere structure and function of the atrium, which in turn would cause electrophysiological abnormalities and sinus node dysfunction. However, it remains to be elucidated whether (1) MYH6 is the causative gene for familial SSS and (2) the genetic variations of MYH6 associated with SSS confer pacemaker dysfunction through structural damage of the sarcomere of the atrial muscle surrounding the sinus node or by functional impairment of the pacemaker channel or sodium channel. The present study identified a novel MYH6 mutation in one SSS proband and investigated the means by which this could confer sinus node dysfunction.
Methods

Genetic Screening of MYH6 Mutations
We previously performed genetic screening of mutations in SCN5A and HCN4 in 15 probands afflicted with familial SSS and found 6 distinct SCN5A mutations. 22 In this study, we enrolled 9 SSS families out of this cohort, which were free from SCN5A or HCN4 mutations. Age at diagnosis of the probands (3 male and 6 female) ranged from 3 to 65 years old (44.6±21.8 years old; mean±SD).
Genomic DNA was extracted from peripheral blood of each subject using standard methods. Coding regions of MYH6 were amplified by polymerase chain reaction using exon-flanking intronic primers ( Table I in 
Alignment of Amino Acid Sequences and Structural Prediction of α-MHC
Amino acid sequence of human α-MHC was aligned using the HomoloGene program with those of other species, and the phylogenetic conservations were testified among human MHC isoforms (the GenBank accession number of each gene is listed in Tables II and III in the Data Supplement). Alterations of the coiled-coil structure of the α-MHC were predicted in silico by using SWISS-MODEL (http://swissmodel.expasy.org/) and visualized by a software RasTop (http://www.geneinfinity.org/rastop/).
Plasmids and cRNA preparation
A 5.8 kb cDNA fragment of human MYH6 was obtained by reverse transcription-polymerase chain reaction from human heart RNA using a primer pair MYH6-F-EcoRV and MYH6-R-Sal1 ( Table I in the Data Supplement) and was cloned into pEGFP-C1 (Takara Bio, Shiga, Japan) to make green fluorescent protein (GFP)-tagged MYH6 plasmid (pEGFP-MYH6). Mutant MYH6 plasmids of R721W (c.2161C>T) and delE933 (c.2797_2799delGAG) were constructed using an overlap-extension polymerase chain reaction strategy.
To assess the binding affinity of the mutant S2 region of α-MHC to myosin-binding protein C (MyBP-C) on the basis of the previous report, 8 cDNAs corresponding to the binding regions for human α-MHC (S2 region; aa. 884-965 of NP_002462) and human MyBP-C (C1C2 region; aa. 256-363 of NP_000247) were amplified and cloned into the c-myc-tag plasmid pCMV-Tag3B (Takara Bio; pCMV3B-MYH6-S2) and the pEGFP-C1 (pEGFP-MYBPC3-C1C2), respectively. All constructs were sequenced to ensure that no errors were introduced.
For the zebrafish experiments, wild-type (WT) and mutant MYH6 cDNA fragments were, respectively, cloned into pIRES2-EGFP vector (Takara Bio; pIRES2-EGFP-MYH6) and pCS2+ vector 23 (pCS2-MYH6) by using specific primer pairs ( Table I in the Data Supplement). cRNAs of human MYH6 were synthesized using the mMessage mMachine in vitro transcription kit (Life Technologies) and purified as described previously. 24 Purified mutant cRNAs were sequenced by the University of Utah sequencing core facility.
Coimmunoprecipitation Assay
HeLa cells were cotransfected with pEGFP-MYBPC3-C1C2 and pC-MV3B-MYH6-S2 using Transfectin lipid reagent (BioRad, Hercules, CA). After 48 hours of the transfection, cells were lysed in protein extraction buffer (1% Nonidet P-40, 1 mmol/L EDTA, 150 mmol/L NaCl, and 10 mmol/L Tris-HCl, pH 7.8) containing Protease Inhibitor Cocktail. Total cellular lysate was obtained by centrifugation at 13 000g for 5 minutes, and its protein concentration was measured by BCA (bicinchoninic acid) protein assay (Thermo Fisher Scientific, Waltham, MA). Coimmunoprecipitation assay was performed using equal amount of cellular lysate with goat anti-myc polyclonal antibody (Sigma-Aldrich, St. Louis, MO) using the Catch and Release version 2.0 reversible immunoprecipitation system (Millipore, Billerica, MA). Immunoprecipitates were separated on a 9% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. After blocking with 5% skim milk in PBS, membranes were incubated with primary anti-GFP monoclonal antibody (1:100, Santa Cruz Biotechnology, Dallas, TX) overnight at 4°C and rabbit-anti mouse IgG horseradish peroxidase (HRP)-conjugated antibody (Dako, Grostrup, Denmark) for 1 hour at RT. Signals were visualized by Immobilon Western Chemiluminescent HRP Substrate (Millipore) and Luminescent Image Analyzer LAS-3000 mini (Fujifilm, Tokyo, Japan).
WHAT IS KNOWN
• Sick sinus syndrome (SSS) is often associated with aging and structural heart diseases, but it may occur in a familial form.
• Recent genome-wide association studies uncovered MYH6 encoding atrial myosin heavy chain as a susceptibility gene for heart rate and SSS; however, its underlying mechanisms and the existence of causative mutations for SSS remain unknown.
• Here, we report a novel MYH6 mutation delE933 in an SSS patient who has a family history of SSS.
WHAT THE STUDY ADDS
• When expressed in cardiomyocytes, delE933-MYH6 impaired the atrial action potential propagation and disrupted sarcomere integrity consistent with the R721W-MYH6, a high risk genetic predisposition for SSS demonstrated in Icelanders.
• Our data reinforces the relevance of MYH6 of sinus node function and suggested that structural damages of the sarcomere and functional impairments on atrial action potential propagation may underlie familial SSS with MYH6 mutations.
Immunofluorescence Study
Immunohistological study was performed using neonatal rat ventricular cardiomyocytes prepared from 1-day-old Sprague-Dawley rats as described previously. 25 Briefly, neonatal rat ventricular cardiomyocytes (4×10 4 ) were transfected with WT or mutant pEGFP-MYH6 plasmid with Lipofectamine LTX. Twenty-four hours later, the cells were fixed with 100% ethanol, stained by primary mouse antiα-actinin antibody (1:100, Sigma-Aldrich) overnight at 4°C and visualized with secondary Alexa Fluor 568 goat antimouse IgG antibody (1:500, Life Technologies). The fluorescent images were analyzed using LSM510 laser-scanning confocal microscope with a 63× oil immersion objective lens (Carl-Zeiss Microscopy, Jena, Germany).
All care and treatment of animals were in accordance with the guidelines for the Care and Use of Laboratory Animals published by the National Institute of Health (NIH Publication, eighth edition 2011) and subjected to prior approval by the animal protection authorities of Nagasaki University and Tokyo Medical and Dental University.
Action Potential Propagation Velocity Measurements in HL-1 Cells Stably Expressing Human MYH6
The mouse atrial cardiomyocyte cell line HL-1 (4×10 5 ), gift from Dr Claycomb, was cultured as previously described. 26 Cells were transfected with 2 μg of linearized pIRES2-EGFP-MYH6 plasmids of WT or delE933 or pIRES2-EGFP plasmid and 4 μl of Lipofectamine LTX (Life Technologies) according to the manufacturer's instructions.
Forty-eight hours after transfection, cells were cultured in the presence of 400 μg/mL G418 (Life Technologies) for 4 weeks to establish stable cell lines.
Stable HL-1 cells (1×10 5 cells) expressing WT-MYH6, delE933-MYH6, or mock pIRES2-EGFP were plated on 8×8 planner multielectrode arrays (array size 1 mm×1 mm; electrode diameter 50 μm; Alpha MED Scientific Inc., Osaka, Japan) precoated with gelatin and fibronectin (Sigma-Aldrich). Seventy-two hours later, a single stimulus of 10 μA was applied on a designated point to initiate spontaneous beating, and electric field potentials were recorded for 1 minute. Action potential propagation velocity was calculated by averaging the velocities between the stimulation point and the remaining 63 points. Cell numbers on the array were counted after recordings with detaching them from the arrays with Trypsin-EDTA. These procedures were repeated 4 times for each line.
In Vivo Evaluation of Overexpressed MYH6 in Zebrafish
Transgenic zebrafish (cmlc2:GFP, Danio rerio) embryos were used to functionally characterize the zebrafish myh6 and human MYH6 variant. MYH6 ATG-blocking morpholino antisense oligonucleotide (myh6 ATG-MO) was designed to target myh6 ( Table I in the Data Supplement). 27 Myh6 ATG-MO (0.5-1 ng/embryo) was injected alone or coinjected with WT or delE933 MYH6 cRNA (0.4 ng/embryo) at the 1-to 2-cell stage. After the injection, embryos were maintained in embryo water at 28°C and staged according to age and morphological criteria. 28 Cardiac phenotypes were screened using A, ECG recordings of the proband (age 62 years) displayed sinus bradycardia (42 beats per minute) with unusual P wave axis and junctional escape beat (last beat in V4-V6). T waves in I-III, aVF, and V4-6 were inverted. B, Holter ECG showed sinus arrest with a maxium RR interval of 5.59 s. C, Echocardiography revealed mild dilatation of left ventricle (LV) and right atrium without obvious evidence for cardiomyopathy, congenital heart disease, or cardiac dysfunction. LV internal diameter, 57 mm; LV posterior and interventricular wall thickness, each 6 mm; LV ejection fraction, 63%. fluorescent microscopy at 48 hour-post-fertilization (hpf). Heart rate and rhythm were recorded. Videos obtained from the embryos were analyzed using Image J (National Institutes of Health) to determine the heart rate and the duration of cardiac pauses.
Statistical Analyses
Results are presented as means±SE otherwise stated, and statistical comparisons were made by using 1-way analysis of variance followed by Bonferroni adjustment to estimate the significance of differences between the mean values of all pairwise. Statistical significance was assumed for P<0.05.
Results
Case Presentation
Genetic screening of MYH6 mutations in 9 probands with familial SSS identified a novel mutation in a 62-year-old Japanese woman. She attended the hospital because of several episodes of presyncope with which she had been afflicted for 5 years. Her 12-lead ECG showed sinus bradycardia (heart rate 42 beats per minute) with unusual P wave axis and junctional escape beat ( Figure 1A) , and Holter ECG revealed sinus arrest with maximum RR interval of 5.59 s ( Figure 1B ). She had no history of other arrhythmias, including atrial fibrillation. Echocardiography revealed mild dilatation of the left ventricle (LV) and right atrium, but there were no obvious signs of cardiomyopathy, congenital heart disease, or cardiac dysfunction (LV internal diameter in diastole, 57 mm; LV posterior wall in diastole, 6 mm; interventricular septal wall in diastole, 6 mm; and LV ejection fraction, 63%; Figure 1C ). A pacemaker was implanted after the diagnosis of SSS. Her deceased mother also had a pacemaker implanted because of SSS during the 7th decade of her life.
Identification of the Novel MYH6 Mutation delE933
The novel mutation identified in the proband was an inframe 3-bp deletion, c.2797_2799delGAG, located in exon 22 of MYH6. This was predicted to delete one residue within the glutamic acid triplet at aa.931-933 of α-MHC (delE933; Figure 2A ). This triplet is located in the S2 segment of α-MHC, a crucial structure required for binding to MyBP-C and for regional phosphorylation of MyBP-C, 6 thereby facilitating a flexible link between thin and thick filaments. The S2 hinge region is highly conserved among α-MHC from different species, as well as between other MHC isoforms ( Figure 2B) .
The proband has no siblings or offspring, and DNA was not available from her deceased mother. The delE933 mutation was not identified in 800 MYH6 alleles from healthy Japanese controls or in the public genetic variation databases of dbSNP, 1000 Genomes, Exome Variant Server, and HGVD. The common variation A1101V was not found in the proband, whereas 3 out of 8 other probands in our cohort were heterozygous for A1101V. The rare MYH6 variation R721W (c.C2161T), associated with SSS in Icelanders, 20 was not found in our familial SSS cohort. No other disease-related mutations were identified in SCN5A, HCN4, SCN3B, KCNJ3, KCNJ5, or GJA5 in our familial SSS cohort. Polymorphisms identified in MYH6 are listed in Table IV in the Data Supplement.
delE933-MYH6 Mutation Disrupts Sarcomere Structures
The S2 segment is a coiled-coil domain of α-MHC composed of a motif of heptad repeats of amino acids. 6, 29, 30 SWISS-MODEL simulation predicted that the delE933 mutation would cause local disruption of the coiled-coil structure ( Figure 3A) . Immunoprecipitation studies using a recombinant MyBP-C C1-C2 protein and WT and delE933α-MHC S2 region proteins expressed in HeLa cells showed that the binding ability of α-MHC with MyBP-C was substantially enhanced by the delE933 mutation ( Figure 3B ).
Because structural damage of sarcomere have been reported in association with MYH6 mutations responsible for atrial
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WT allele delE933 allele septal defect, 7 we next explored whether the MYH6 variation R721W, as well as delE933, disrupted integrity of sarcomere structures. To investigate the functional consequences of MYH6 mutations on the atrial sarcomere structure, we used a heterologous expression system in cultured rat cardiomyocytes in which the predominant ventricle MHC isoform is α-MHC. 31 Neonatal rat ventricular cardiomyocytes were transiently transfected with a GFP-tagged MYH6 WT, delE933, or R721W plasmids. Confocal microscopy analysis revealed comparable GFP intensities after transfection of all 3 MYH6 plasmids (Figure 3C , a-c), indicating that the expression levels and stability of heterologously expressed α-MHC proteins were similar. Endogenous sarcomeric α-actinin expression at the Z-disc indicated the sarcomere integrity of transfected myocardial cells ( Figure 3C , d-f). Cells expressing WT-MYH6 displayed a striated staining pattern, indicating that heterologous α-MHC was correctly integrated into the sarcomere. However, both MYH6 mutants, delE933 and R721W, exhibited a substantially disrupted α-actinin staining pattern and perinuclear aggregation of α-MHC, suggesting that structural damage to the sarcomere had occurred in cells expressing MYH6 variants predisposing to sinus node dysfunction.
Atrial HL-1 Cells Stably Expressing the delE933-MYH6 Showed Impaired Electric Propagation
A recent genome-wide association study showed that the Iceland-specific MYH6 variant was significantly associated with atrial fibrillation, 20 we hypothesized that the functional defects caused by mutated MYH6 may affect action potential propagation in the atrium surrounding the sinus node, leading to SSS manifestation. We cultured the mouse atrial cardiomyocyte cell line HL-1 stably expressing WT or mutant MYH6 on 64-well electrode arrays and analyzed electric propagation velocities ( Figure 4A ). The propagation velocity was unchanged between WT-MYH6 and control mock-transfected cells, but cells expressing delE933-MYH6 exhibited a significantly slower propagation velocity (control, 3.6±0.6 mm/s; WT, 3.8±1.2 mm/s; delE933, 2.9±0.8 mm/s; n=252 for each line, P<0.001 for WT versus delE933; Figure 4B ). Cell numbers of each array were comparable (P=0.49; Table V in the Data Supplement). These data suggest that mutant MYH6 delE933 impairs cell-to-cell action potential propagation in the atrial myocardium.
delE933-MYH6 Failed to Rescue the Heart Rate Reduction in Zebrafish With Morpholino myh6 Knockdown
To determine whether the human MYH6 orthologue myh6 could influence heart rate control in zebrafish, we performed targeted myh6 knockdown experiments with ATG-MO. Zebrafish cardiac phenotypes, including heart rate and cardiac rhythm, were assessed at 48 hpf. The myh6 morphants exhibited atrial dilatation ( Figure 4C ), which is consistent with a previous report using decreased functional myh6 transcript. 27 Myh6 morphants also showed a significantly slower heart rate than uninjected embryos (myh6-MO, 137.7±2.2 beats per minute, n=28; uninjected 150.2±1.6 beats per minute, n=25; P<0.001; Figure 4D ). Cardiac asystole was not observed in uninjected embryos or morphants. As shown in Figure 4D , coinjection of WT human MYH6 cRNA rescued the bradycardia (148.7±1.4 beats per minute, n=26; versus myh6-MO P<0.001), suggesting that the human MYH6 compensated for the loss of the zebrafish orthologue. By contrast, human MYH6 carrying the delE933 mutation failed to rescue the bradycardia (142.3±2.5 beats per minute, n=24). Human MYH6 RNA was detected by reverse transcriptionpolymerase chain reaction in embryos at 24 and 48 hours after injection (Figure in the Data Supplement), suggesting that the delE933 mutation of MYH6 is responsible for sinus node dysfunction. The S2 fragment of delE933 shows increased binding to the C1C2 fragment of MyBP-C. A nonspecific double band was often observed on the input of a mock pEGFP-C1 plasmid (third column). C, Fluorescence images of neonatal rat ventricular cardiomyocytes transiently expressing wild-type (WT), delE933, or R721W MYH6 fused to green fluorescent protein (GFP). WT α-MHC shows a striated pattern of GFP together with the proper striated sarcomeric pattern of α-actinin (a and d) . α-MHC with mutations of R721W and delE933 show brightly fluorescent speckles without well-organized sarcomere structure (b and c) . The α-actinin images show a misaligned and disrupted pattern of myofibrils (e and f), indicating sarcomere disintegration. Scale bar, 10 μm.
Discussion
A growing body of evidence from genome-wide association studies has demonstrated an association of MYH6 with sinus node function. [17] [18] [19] [20] A common nonsynonymous single-nucleotide polymorphism of MYH6 (A1101V) was previously shown to be a genetic modifier for resting heart rate and PR interval, 18 and this was further replicated in a large meta-analysis, including subjects of European ancestry from both the United States and Europe. 17, 19 A combination of A1101V with other loci controlling heart rate further reduced the risk of SSS and pacemaker implantation, implicating a heritable quantitative trait. 17 By contrast, the rare MYH6 variation R721W, unique to Icelanders, predisposes individuals to SSS and pacemaker implantation. 20 These studies clearly demonstrate that MYH6 is a genetic modifier of sinus node function, but the mechanisms of this have been unclear, and it was uncertain whether MYH6 could be a causative gene of familial SSS. In this study, we identified a novel MYH6 mutation, delE933, in one SSS individual among 9 probands of our familial SSS cohort. 22 We found that the mutant delE933-MYH6 slowed down action potential propagation when heterologously expressed in the atrial myocardial cell line HL-1 ( Figure 4A ). Moreover, knockdown of endogenous MYH6 leading to reduced heart rate in zebrafish could be compensated for by the coexpression of WT-MYH6 but not by delE933-MYH6 ( Figure 4B ). To our knowledge, this is the first experimental evidence demonstrating that MYH6 variations can influence heart rate and action potential propagation. However, limited information is available to delineate the functional link between sarcomere components and sinus node function, and it remains unknown whether α-MHC directly affects pacemaker function or whether its actions are mediated though undefined mechanisms.
The delE933 mutation is located in the coiled-coil structure of the α-MHC S2 region, a binding motif for MyBP-C, and so is predicted to alter the tertiary structure and the crosslinking affinity between 2 sarcomere components (Figure 2A  and 2B ). Although the final consequences of such structural and functional modifications are unknown, a previous study that the MyBP-C mutation E334K, responsible for hypertrophic cardiomyopathy, impaired the ubiquitin-proteasome system, leading to an accumulation of cardiac ion channels at the sarcomere and electrophysiological dysfunction. 32 Increased protein levels were also observed for several other cardiac ion channels, including Kv1.5, Nav1.5, HCN4, Cav3.2, Cav1.2, SERCA, RYR2, and NCX1, which play major roles in controlling normal pacemaker function and atrial conductivity. Based on these findings, we speculate that an abnormal association between delE933-α-MHC and MyBP-C might modulate the expression of cardiac ion channels that affect pacemaker function, which in turn would lead to the development of SSS.
In the present study, overexpression of the SSS-susceptible α-MHC mutants of R721W and delE933 in neonatal rat ventricular cardiomyocytes impaired sarcomere structures. However, it is unknown whether MYH6 mutations preferentially impair the sinus node function or whether they might eventually cause further extensive electric damage manifesting as atrial fibrillation. Because the patient did not undergo electrophysiological studies or cardiac biopsy, further information regarding the spatial distribution and heterogeneity of pathological damages and electrophysiological abnormalities in the atrium is not available. Nevertheless, the T wave inversion of ECG and mild dilatation of the right atrium and LV ( Figure 1A and 1B ) are in accordance with the observation that targeted myh6 knockdown in zebrafish induced the atrial dilatation associated with negative chronotropic effects, indicating that MYH6 mutations may directly cause substantial damage and electric disorder to the myocardium in the atrium. This idea is further supported by the finding that heterozygous zebrafish expressing the MYH6 mutation N695K (MYH6 hu/423/+ ) exhibited loss of atrial contractility, with residual beating restricted to the region near the atrioventricular junction and sinus venosus. 21 These observations strongly suggest that the final consequences of MYH6 mutations in humans might also exhibit considerable heterogeneity with respect to the structural and electrophysiological properties of the atrium and sinus node. 33, 34 Furthermore, these structural abnormalities of atrial sarcomere may extend to more severe conduction dysfunctions, such as atrial fibrillation or contractile failure, depending on the functional severity caused by each mutation. The slower conduction velocity observed in the HL-1 cells stably expressing delE933-MYH6 in the present study suggests the possible involvement of MYH6 in conduction dysfunction. This idea is supported by a recent genome-wide association study in which correlation studies of the MYH6 variant R721W exhibited a significantly higher association with atrial fibrillation both before (odds ratio, 2.39; P=0.00010) and after (odds ratio, 2.03; P=0.015) exclusion of known SSS cases. 20 It is of note that the R719W of the ventricular β-MHC gene MYH7, homologous to the R721W-MYH6, is responsible for a malignant hypertrophic cardiomyopathy frequently associated with conduction abnormalities, 35 suggesting that α-MHC and β-MHC may share some pathophysiological mechanisms affecting cardiac action potential propagation.
SSS commonly occurs in older individual in the absence of accompanying heart diseases but comprises a variety of electrophysiological abnormalities in sinus node impulse formation and propagation. Although less common, SSS also shows familial inheritance, and implicated causative genes include those encoding cardiac ion channels, such as SCN5A. We recently found that familial SSS probands carrying SCN5A mutations showed a significantly earlier disease onset and a strong male predominance, whereas nonfamilial SSS had a disease onset of over 70 years for both sexes, which were affected equally. 22 The affected members of the SSS family in the present study were both women, aged over 60 years, suggesting that familial SSS with MYH6 mutations might constitute an SSS subgroup distinct from that caused by SCN5A mutations. This may suggest the existence of a new disease entity of inherited arrhythmias attributable to mutations in genes encoding sarcomere proteins other than cardiac ion channel or ion channel-associated genes.
Limitation of the Study
Lack of information about the genotype-phenotype cosegregation of delE933-MYH6 is the major limitation of this study from the standpoint of human genetics. Although bioinformatics evaluations, as well as in vitro and in vivo studies, have suggested pathophysiological significance of the rare MYH6 variation delE933, it still does not exclude the possibility that the proband manifested SSS attributable to factors, such as aging rather than the MYH6 mutation. To demonstrate the causality between SSS and MYH6, more extensive genetic screenings in patients with familial SSS to find novel MYH6 mutations are required. Furthermore, it remains to be elucidated how the impaired sarcomere structures and conduction velocity elicited by delE933-MYH6 ultimately result in the sinus node dysfunction. Electrophysiological studies using induced pluripotent stem cell-derived cardiomyocytes from MYH6 mutation carriers, as well as basic evaluations of MYH6 using genetically engineered animals, are also warranted.
